Eledon Pharmaceuticals, Inc.
DE ˙ DB ˙ US28617K1016
2,92 € ↓ −0,04 (−1,35%)
2026-06-04
DELAT PRIS
SecurityDE:2TK / Eledon Pharmaceuticals, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership0 shares
Ownership 0.00%
Vanguard Group Inc ownership in 2TK / Eledon Pharmaceuticals, Inc.

2026-03-26 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Eledon Pharmaceuticals, Inc. (DE:2TK). This represents 0.0 percent ownership of the company. In their previous filing dated 2025-07-29 , Vanguard Group Inc had reported owning 3,318,383 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-03-26 2026-03-26 13G/A 3,318,383 0 -100.00 0.00 -100.00
2025-07-29 2025-07-29 13G 3,318,383 5.54

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 4,039,686 771,903 23.62 6,100 -27.93 0.0001
2025-11-07 2025-09-30 13F ELEDON PHARMACEUTICALS COM 28617K101 3,267,783 -50,600 -1.52 8,464 -5.88 0.0001
2025-08-11 2025-06-30 13F ELEDON PHARMACEUTICALS COM 28617K101 3,318,383 365,256 12.37 8,993 -10.18 0.0001
2025-05-09 2025-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 2,953,127 58,488 2.02 10,011 -16.05 0.0002
2025-02-11 2024-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 2,894,639 1,329,152 84.90 11,926 205.93 0.0002
2024-11-13 2024-09-30 13F ELEDON PHARMACEUTICALS COM 28617K101 1,565,487 461,092 41.75 3,898 33.72 0.0001
2024-08-13 2024-06-30 13F ELEDON PHARMACEUTICALS COM 28617K101 1,104,395 135,274 13.96 2,916 46.04 0.0001
2024-05-10 2024-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 969,121 273,703 39.36 1,996 59.55 0.0000
2024-03-11 2023-12-31 13F/A-1 ELEDON PHARMACEUTICALS COM 28617K101 695,418 20,898 3.10 1,252 35.39 0.0000
2024-02-14 2023-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 695,418 20,898 1,252 0.0000
2023-12-18 2023-09-30 13F/A-1 ELEDON PHARMACEUTICALS COM 28617K101 674,520 -5,037 -0.74 924 -0.65 0.0000
2023-11-14 2023-09-30 13F ELEDON PHARMACEUTICALS COM 28617K101 674,520 -5,037 924 0.0000
2023-08-14 2023-06-30 13F ELEDON PHARMACEUTICALS COM 28617K101 679,557 0 0.00 931 -41.98 0.0000
2023-07-14 2023-03-31 13F/A-1 ELEDON PHARMACEUTICALS COM 28617K101 679,557 0 0.00 1,604 3.49 0.0000
2023-05-15 2023-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 679,557 0 1,604 0.0000
2023-02-10 2022-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 679,557 314 0.05 1,549 -17.39 0.0000
2022-11-14 2022-09-30 13F ELEDON PHARMACEUTICALS COM 28617K101 679,243 0 0.00 1,875 13.16 0.0001
2022-08-12 2022-06-30 13F ELEDON PHARMACEUTICALS COM 28617K101 679,243 0 0.00 1,657 -38.08 0.0000
2022-05-13 2022-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 679,243 9,543 1.42 2,676 -9.38 0.0001
2022-02-14 2021-12-31 13F ELEDON PHARMACEUTICALS COM 28617K101 669,700 -813 -0.12 2,953 -28.72 0.0001
2021-11-12 2021-09-30 13F ELEDON PHARMACEUTICALS COM 28617K101 670,513 460,763 219.67 4,143 149.73 0.0001
2021-08-13 2021-06-30 13F ELEDON PHARMACEUTICALS COM 28617K101 209,750 -20,294 -8.82 1,659 -32.59 0.0000
2021-05-14 2021-03-31 13F ELEDON PHARMACEUTICALS COM 28617K101 230,044 226,001 5,589.93 2,461 3,869.35 0.0001
2021-02-12 2020-12-31 13F NOVUS THERAPEUTICS COM 67011N204 4,043 -50,747 -92.62 62 19.23 0.0000
2020-11-16 2020-09-30 13F NOVUS THERAPEUTICS COM 67011N105 54,790 0 0.00 52 108.00 0.0000
2020-08-14 2020-06-30 13F NOVUS THERAPEUTICS COM 67011N105 54,790 17,100 45.37 25 66.67 0.0000
2020-05-15 2020-03-31 13F NOVUS THERAPEUTICS COM 67011N105 37,690 0 0.00 15 -31.82 0.0000
2020-02-14 2019-12-31 13F NOVUS THERAPEUTICS COM 67011N105 37,690 -25,071 -39.95 22 -43.59 0.0000
2019-11-14 2019-09-30 13F NOVUS THERAPEUTICS COM 67011N105 62,761 -207,399 -76.77 39 -85.71 0.0000
2019-08-14 2019-06-30 13F NOVUS THERAPEUTICS COM 67011N105 270,160 227,157 528.24 273 57.80 0.0000
2019-05-15 2019-03-31 13F NOVUS THERAPEUTICS COM 67011N105 43,003 600 1.41 173 154.41 0.0000
2019-02-14 2018-12-31 13F NOVUS THERAPEUTICS COM 67011N105 42,403 -93,196 -68.73 68 -89.26 0.0000
2018-12-13 2018-09-30 13F/A-2 NOVUS THERAPEUTICS COM 67011N105 135,599 57,450 73.51 633 15.72 0.0000
2018-11-23 2018-09-30 13F/A-1 NOVUS THERAPEUTICS COM 67011N105 135,599 0 633 0.0000
2018-11-14 2018-09-30 13F NOVUS THERAPEUTICS COM 67011N105 135,599 57,450 633
2018-08-14 2018-06-30 13F NOVUS THERAPEUTICS COM 67011N105 78,149 34,238 77.97 547 158.02 0.0000
2018-05-15 2018-03-31 13F NOVUS THERAPEUTICS COM 67011N105 43,911 425 0.98 212 26.19 0.0000
2018-02-14 2017-12-31 13F NOVUS THERAPEUTICS COM 67011N105 43,486 -1,582 -3.51 168 -28.51 0.0000
2017-11-14 2017-09-30 13F NOVUS THERAPEUTICS COM 67011N105 45,068 2,265 5.29 235 -6.37 0.0000
2017-08-24 2017-06-30 13F/A-1 NOVUS THERAPEUTICS COM 67011N105 42,803 -367,010 -89.56 251 -26.82 0.0000
2017-08-11 2017-06-30 13F NOVUS THERAPEUTICS COM 67011N105 42,803 251
2017-05-12 2017-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 409,813 75,450 22.57 343 4.89 0.0000
2017-02-14 2016-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 334,363 222,909 200.00 327 91.23 0.0000
2016-11-14 2016-09-30 13F TOKAI PHARMACEUTICALS COM 88907J107 111,454 -145,128 -56.56 171 -87.91 0.0000
2016-08-10 2016-06-30 13F TOKAI PHARMACEUTICALS COM 88907J107 256,582 7,097 2.84 1,414 1.07 0.0001
2016-05-13 2016-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 249,485 9,019 3.75 1,399 -33.29 0.0001
2016-02-08 2015-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 240,466 10,510 4.57 2,097 -11.89 0.0001
2015-11-12 2015-09-30 13F/A-1 TOKAI PHARMACEUTICALS COM 88907J107 229,956 28,244 14.00 2,380 -11.29 0.0001
2015-11-12 2015-09-30 13F/A-1 TOKAI PHARMACEUTICALS COM 88907J107 229,956 28,244 2,380 0.0001
2015-08-13 2015-06-30 13F TOKAI PHARMACEUTICALS COM 88907J107 201,712 10,039 5.24 2,683 23.87 0.0002
2015-05-15 2015-03-31 13F/A-1 TOKAI PHARMACEUTICALS COM 88907J107 191,673 33,317 21.04 2,166 -7.20 0.0001
2015-05-14 2015-03-31 13F TOKAI PHARMACEUTICALS COM 88907J107 191,673 2,166
2015-02-12 2014-12-31 13F TOKAI PHARMACEUTICALS COM 88907J107 158,356 158,356 2,334 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.